Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice

Digestive Diseases and Sciences

Volumn 52, Issue 1, 2007, Pages 84-92

  Laharie, David ^a   Ménard, Sandrine ^a   Asencio, Corinne ^a   Vidal Martinez, Teresita ^a   Rullier, Anne ^b   Zerbib, Frank ^a   Candalh, Céline ^a   Mégraud, Francis ^a   Heyman, Martine ^a   Matysiak Budnik, Tamara ^a  

^a INSERM   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Colitis; Immune response; Interleukin 10; Intestinal permeability; Rebamipide

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; REBAMIPIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HELICOBACTER HEPATICUS; HISTOLOGY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT;

EID: 33846299975     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9183-4     Document Type: Article

References (41)

1. Meddings JB (1997) Review article: intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 11(Suppl 3):47-53
2. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, Riecken EO, Schulzke JD (1999) Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116:301-309
3. Soderholm JD, Olaison G, Peterson KH, Franzen LE, Lindmark T, Wiren M, Tagesson C, Sjodahl R (2002) Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 50:307-313
4. Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH (2001) Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol 158:1101-1109
5. Irvine EJ, Marshall JK (2000) Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 119:1740-1744
6. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (1998) Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43:5S-13S
7. Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Megraud F (2000) Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis. Scand J Gastroenterol 35:470-475
8. Matysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M (2001) Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide. Dig Dis Sci 46:1558-1566
9. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y (2000) Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608-1616
10. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL (2000) Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838-1839
11. Li X, Fox JG, Whary MT, Yan L, Shames B, Zhao Z (1998) SCID/NCr mice naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis, and colitis. Infect Immun 66:5477-5484
12. Shomer NH, Dangler CA, Schrenzel MD, Fox JG (1997) Helicobacter bilis-induced inflammatory bowel disease in SCID mice with defined flora. Infect Immun 65:4858-4864
13. Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, Jankovic D, Sher A (1998) Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 66:5157-5166
14. Fox JG, Dewhirst FE, Shen Z, Feng Y, Taylor NS, Paster BJ, Ericson RL, Lau CN, Correa P, Araya JC, Roa I (1998) Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 114:755-763
15. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F (2003) Double-blind, placebo-controlled trial of two probiotic strains in interleukin-10 knockout mice and mechanistic link with cytokine balance. Gut 52:975-980
16. Maehly AC, Chance B (1954) The assay of catalases and peroxidases. In: Glick D (ed) Methods of biochemical analysis, vol 1. Wiley Interscience, New York, pp 357-398
17. Matysiak-Budnik T, van Niel G, Megraud F, Mayo K, Bevilacqua C, Gaboriau-Routhiau V, Moreau MC, Heyman M (2003) Gastric Helicobacter infection inhibits development of oral tolerance to food antigens in mice. Infect Immun 71:5219-5224
18. Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M (1995) Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Rad Biol Med 18:117-123
19. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S (1987) Gastric mucosal protection by OPC-12759, a novel antiulcer compound in rat. Eur J Pharmacol 142:29
20. Soderholm JD, Peterson KH, Olaison G, Franzen LE, Westrom B, Magnusson KE, Sjodahl R (1999) Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease? Gastroenterology 117:65-72
21. Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH (2004) Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 53:1817-1824
22. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97:2000-2004
23. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M (1998) Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43:160S-166S
24. Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K (1998) Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43:174S-180S
25. Danielsson D, Jurstrand M (1998) Nonopsonic activation of neutrophils by Helicobacter pylori is inhibited by rebamipide. Dig Dis Sci 43:167S-173S
26. Nagano C, Wakebe H, Azuma A, Imagawa K, Kikuchi M (1998) IFN-gamma-induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells. Dig Dis Sci 43:118S-124S
27. Bamba H, Ota S, Kato A, Miyatani H, Kawamoto C, Yoshida Y, Fujiwara K (2003) Effect of rebamipide on prostaglandin receptors-mediated increase of inflammatory cytokine production by macrophages. Aliment Pharmacol Ther 18(Suppl 1):113-118
28. Iwai A, Iwashita E (1998) Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig Dis Sci 43:143S-147S
29. Sakurai K, Osaka T, Yamasaki K (1998) Protection by rebamipide against acetic acid-induced colitis in rats: relationship with its antioxidative activity. Dig Dis Sci 43:125S-133S
30. Hahm KB, Kim DH, Lee KM, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Joo HJ, Cho YK, Nam KT, Cho SW (2003) Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther 18(Suppl 1):24-38
31. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T (1995) Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG.Vaccine 13:310-312
32. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M (2004) Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53:821-828
33. Benyacoub J, Czarnecki-Maulden GL, Cavadini C, Sauthier T, Anderson RE, Schiffrin EJ, von der WT (2003) Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs. J Nutr 133:1158-1162
34. Benyacoub J, Perez PF, Rochat F, Saudan KY, Reuteler G, Antille N, Humen M, De Antoni GL, Cavadini C, Blum S, Schiffrin EJ (2005) Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in mice. J Nutr 135:1171-1176
35. Pelto L, Salminen SJ, Isolauri E (1998) Lactobacillus GG modulates milk-induced immune inflammatory response in milk-hypersensitive adults. Nutrition Today 31(Suppl):45S-46S
36. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M (2004) Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53:821-828
37. Madara JL, Stafford J (1989) Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83:724-727
38. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429
39. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113:1490-1497
40. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98:1010-1020
41. Dieleman LA, Arends A, Tonkonogy SL, Goerres MS, Craft DW, Grenther W, Sellon RK, Balish E, Sartor RB (2000) Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect Immun 68:5107-5113